Juvenescence
PrivateLast Round
Series B
Extension
May 21, 2025
Est. Valuation
$500M
Total Funding Raised
$163M
Company Overview
Juvenescence is a biotechnology company that develops medicines and therapies designed to extend healthy human lifespan by targeting the core mechanisms of aging.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, D2C Brands, Sports & Fitness
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Juvenescence Comparables
Compare Juvenescence with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cambrian Bio | 87% | |
| BioAge Labs | 78% | |
| Altos Labs | 77% |
Juvenescence Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 21, 2025 | ||||
| Series B | Aug 19, 2019 | ||||
| Series A | Jun 11, 2018 | ||||
| Seed | Jan 8, 2018 |
Key People
Founding team and executive leadership
Juvenescence Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Grok Ventures | Series B |
| IPGL | Series B |
| SEED Innovations Limited | Series A |
| Apeiron Investment Group | Seed |
| Foresite Capital | Seed |
| Oryx Ventures | Series B |
| SEED Innovations | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2025
Attended the Middle East Investors Summit in Abu Dhabi.
- Jun 5, 2025
Acquired Ro5 Inc. for $76 million.
Juvenescence Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Juvenescence's valuation, stock price, and market status.
Is Juvenescence a public or private company?
Juvenescence is a private company.
What is the current stock price of Juvenescence?
Juvenescence is a private company with no public stock price. No recent secondary market data is available.
How much is Juvenescence worth (valuation)?
Juvenescence's valuation is estimated at $500.0M based on funding round data.
Can I buy Juvenescence stock?
Juvenescence shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Juvenescence's last funding round?
Juvenescence's most recent funding round was Series B Extension on August 19, 2019.
Who are the main investors in Juvenescence?
Key investors in Juvenescence include Grok Ventures, IPGL, SEED Innovations Limited, Apeiron Investment Group, Foresite Capital.
Will Juvenescence IPO soon?
No public IPO plans have been announced for Juvenescence.
How can I track Juvenescence secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Juvenescence's secondary market activity and sign up for updates.